Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Portfolio Pulse from Benzinga Insights
Myriad Genetics (NASDAQ:MYGN) has been analyzed by 5 analysts, revealing mixed sentiments. The average 12-month price target is $25.8, with a high of $30.00 and a low of $20.00. Recent analyst actions include rating adjustments and price target changes, reflecting varied expectations for the company's performance.
August 13, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Myriad Genetics has received mixed analyst ratings, with a 12-month price target average of $25.8. Recent actions include rating adjustments and price target changes, indicating varied expectations for the company's performance.
The mixed analyst ratings and varied price targets suggest uncertainty about Myriad Genetics' short-term performance. While some analysts have raised their price targets, others have lowered them, indicating a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100